BRPI0913410A2 - uso de uma nanopartícula ou agregado de nanopartícula, e, composição farmacêutica - Google Patents

uso de uma nanopartícula ou agregado de nanopartícula, e, composição farmacêutica

Info

Publication number
BRPI0913410A2
BRPI0913410A2 BRPI0913410A BRPI0913410A BRPI0913410A2 BR PI0913410 A2 BRPI0913410 A2 BR PI0913410A2 BR PI0913410 A BRPI0913410 A BR PI0913410A BR PI0913410 A BRPI0913410 A BR PI0913410A BR PI0913410 A2 BRPI0913410 A2 BR PI0913410A2
Authority
BR
Brazil
Prior art keywords
nanoparticle
pharmaceutical composition
aggregate
nanoparticle aggregate
pharmaceutical
Prior art date
Application number
BRPI0913410A
Other languages
English (en)
Inventor
Agnès Pottier
Annabelle Rouet
Corinne Devaux
Julie Marill
Laurent Levy
Matthieu Germain
Original Assignee
Nanobiotix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobiotix filed Critical Nanobiotix
Publication of BRPI0913410A2 publication Critical patent/BRPI0913410A2/pt
Publication of BRPI0913410B1 publication Critical patent/BRPI0913410B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Radiation-Therapy Devices (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0913410-7A 2008-06-05 2009-06-04 Uso de uma nanopartícula ou agregado de nanopartícula, e, composição farmacêutica BRPI0913410B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08157686A EP2130553A1 (en) 2008-06-05 2008-06-05 Inorganic nanoparticles of high density to destroy cells in-vivo
EP08157686.0 2008-06-05
US6020208P 2008-06-10 2008-06-10
US61/060202 2008-06-10
PCT/EP2009/056880 WO2009147214A2 (en) 2008-06-05 2009-06-04 Inorganic nanoparticles, preparation and uses thereof

Publications (2)

Publication Number Publication Date
BRPI0913410A2 true BRPI0913410A2 (pt) 2015-11-24
BRPI0913410B1 BRPI0913410B1 (pt) 2021-09-21

Family

ID=39734334

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0913410-7A BRPI0913410B1 (pt) 2008-06-05 2009-06-04 Uso de uma nanopartícula ou agregado de nanopartícula, e, composição farmacêutica

Country Status (26)

Country Link
US (1) US8845507B2 (pt)
EP (4) EP2130553A1 (pt)
JP (1) JP5734181B2 (pt)
KR (1) KR101639281B1 (pt)
CN (1) CN102056628B (pt)
AU (1) AU2009254550B2 (pt)
BR (1) BRPI0913410B1 (pt)
CA (1) CA2727576C (pt)
CY (2) CY1118217T1 (pt)
DK (2) DK2300054T3 (pt)
EA (1) EA023012B1 (pt)
ES (2) ES2702249T3 (pt)
HR (2) HRP20161465T8 (pt)
HU (2) HUE040247T2 (pt)
IL (1) IL209625A (pt)
LT (2) LT3150227T (pt)
MA (1) MA32453B1 (pt)
MX (1) MX2010013322A (pt)
NZ (1) NZ589888A (pt)
PL (2) PL3150227T3 (pt)
PT (2) PT2300054T (pt)
SG (1) SG10201405288WA (pt)
SI (2) SI3150227T1 (pt)
TR (1) TR201819077T4 (pt)
WO (1) WO2009147214A2 (pt)
ZA (1) ZA201100082B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004075975A2 (en) * 2003-02-24 2004-09-10 Pomper Mark E Mobile radiation treatment vehicle and method
US8459714B2 (en) 2006-05-19 2013-06-11 Breya, Llc. Mobile radiation therapy
US8657354B2 (en) 2006-05-19 2014-02-25 Breya, Llc. Mobile radiation therapy
US8728440B2 (en) 2012-08-23 2014-05-20 General Electric Company Nanoparticulate compositions for diagnostic imaging
US9399075B2 (en) 2008-12-29 2016-07-26 General Electric Company Nanoparticle contrast agents for diagnostic imaging
US9585840B1 (en) 2009-07-10 2017-03-07 University Of Central Florida Research Foundation, Inc. Redox active cerium oxide nanoparticles and associated methods
EP2275137A1 (en) 2009-07-10 2011-01-19 Nanobiotix Metallic nanoparticles, preparation and uses thereof
CN102870235B (zh) 2009-11-10 2016-11-23 免疫之光有限责任公司 用于从包括用于上变频的射频、微波能量和磁感应源的各种能量源产生发射光的上下变频系统
WO2012058271A2 (en) 2010-10-27 2012-05-03 Pixelligent Technologies, Llc Synthesis, capping and dispersion of nanocrystals
CN102947218B (zh) * 2010-04-23 2016-05-11 皮瑟莱根特科技有限责任公司 纳米晶体的合成、盖帽和分散
US9359689B2 (en) 2011-10-26 2016-06-07 Pixelligent Technologies, Llc Synthesis, capping and dispersion of nanocrystals
JP6042450B2 (ja) 2011-12-16 2016-12-14 ナノビオティックスＮａｎｏｂｉｏｔｉｘ 金属材料および酸化ハフニウム材料を含むナノ粒子、その製造および使用
US20150141875A1 (en) * 2012-06-14 2015-05-21 The Board Of Trustees Of The University Of Arkansas Compositions and methods for non-invasive detection and treatment of hypoxic cells in vivo
US8821838B2 (en) 2012-08-23 2014-09-02 General Electric Company Nanoparticulate compositions for diagnostic imaging
PL2948179T3 (pl) * 2013-01-25 2019-10-31 Nanobiotix Kompozycje zawierające nanocząstki tlenku hafnu(iv) lub tlenku renu(iv) w połączeniu z promieniowaniem jonizującym do leczenia nowotworu
JP6693868B2 (ja) * 2013-02-19 2020-05-13 ナショナル ヘルス リサーチ インスティテューツＮａｔｉｏｎａｌ Ｈｅａｌｔｈ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅｓ 抗癌化学療法剤用のケージ化された白金ナノクラスタ
MA38687A1 (fr) 2013-05-30 2017-12-29 Nanobiotix Composition pharmaceutique, préparation et utilisations de celle-ci
AU2014283217A1 (en) * 2013-06-20 2015-12-24 Nanobiotix Compositions and methods for use in medical diagnosis
BR112016012410A2 (pt) * 2013-12-16 2017-09-26 Genentech Inc conjugado de droga e anticorpo, composto conjugado de droga e anticorpo, composto não-peptídico, método de tratamento de doenças em seres humanos e composição farmacêutica
EP2886128A1 (en) 2013-12-20 2015-06-24 Nanobiotix Pharmaceutical composition comprising nanoparticles, preparation and uses thereof
DK3223796T3 (da) 2014-11-25 2021-09-27 Curadigm Sas Farmaceutiske sammensætninger, fremstilling og anvendelser deraf
AU2015352685B2 (en) 2014-11-25 2020-09-17 Nanobiotix Pharmaceutical composition, preparation and uses thereof
WO2016083336A1 (en) 2014-11-25 2016-06-02 Nanobiotix Pharmaceutical composition, preparation and uses thereof
PL3229843T3 (pl) 2014-11-25 2020-06-29 Curadigm Sas Kompozycja farmaceutyczna, wytwarzanie i zastosowanie tej kompozycji
PT3229776T (pt) 2014-11-25 2023-08-17 Curadigm Sas Composição farmacêutica combinando pelo menos duas nanopartícuas distintas e um composto farmacêutico, preparaçâo e suas utilizações
WO2016112268A1 (en) * 2015-01-08 2016-07-14 Purdue Research Foundation Radio-luminescent particles for enhancement of radiation cancer therapy
JP2018516256A (ja) * 2015-05-28 2018-06-21 ナノビオティックスＮａｎｏｂｉｏｔｉｘ 治療用ワクチンとしての使用のためのナノ粒子
US11389536B2 (en) 2015-07-17 2022-07-19 BioCurity Pharmaceuticals Inc. Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
CN109010828B (zh) * 2018-10-12 2020-10-20 中国科学院高能物理研究所 一种二硫化钼/二氧化铪的复合纳米材料、其制备方法及用途
CN109616308B (zh) * 2018-11-07 2020-09-04 湖北第二师范学院 一种球形纳米氧化铱dna提取磁性粉末及其生产方法
CN109771645B (zh) * 2019-03-07 2021-08-24 广西师范大学 一种二氧化钌复合卵清蛋白纳米材料的制备及其应用
EP4157457A1 (en) * 2020-05-26 2023-04-05 Nanobiotix Nanoparticles, ionizing radiation and innovative therapeutic combinations thereof
AU2021374754A1 (en) * 2020-11-05 2023-06-22 Nanobiotix Compositions of nanoparticles for treatment of cancer
EP4255488A1 (en) * 2020-12-01 2023-10-11 Nanobiotix Porous, high-z and carbon-free particles as radioenhancers
CA3234824A1 (en) * 2021-11-23 2023-06-01 Universitat Basel Hafnium (iv) oxide nanoparticles and aqueous compositions thereof
AR131316A1 (es) 2022-12-12 2025-03-05 Nanobiotix S A Novedosas nanopartículas de óxido de metal y composiciones de las mismas para uso como radiopotenciadores o para visualizar tejido biológico
EP4595983A1 (en) 2024-02-05 2025-08-06 BXTA Nanotherapy Limited Nanoparticles functionalised with a stabilising agent and a targeting agent
WO2026074471A1 (en) * 2024-10-02 2026-04-09 Janssen Pharmaceutica Nv Combination therapies with hafnium oxide nanoparticles and pd-l1 antibodies for use in the treatment of non small cell lung cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6287526A (ja) * 1985-10-11 1987-04-22 Akira Fujishima 抗腫瘍剤
WO2000006244A2 (en) 1998-07-30 2000-02-10 Hainfeld James F Loading metal particles into cell membrane vesicles and metal particle use for imaging and therapy
EP1696957A2 (en) 2003-12-17 2006-09-06 Philips Intellectual Property & Standards GmbH Radiation therapy and medical imaging using uv emitting nanoparticles
FR2869803B1 (fr) * 2004-05-10 2006-07-28 Nanobiotix Sarl Particules activables, preparation et utilisations
US20070092927A1 (en) * 2005-06-13 2007-04-26 University Of Dayton Photocatalytic particles with directed and controlled redox activity
JP2007075696A (ja) * 2005-09-13 2007-03-29 Mitsubishi Materials Corp 多孔質光触媒膜
RU2009104312A (ru) * 2006-07-10 2010-08-20 Конинклейке Филипс Электроникс Н.В. (Nl) Наночастицы типа "ядро-оболочка" для терапии и диагностических целей
EP1920784A1 (en) * 2006-11-13 2008-05-14 Koninklijke Philips Electronics N.V. Radiation sensitizers in ionizing radiation therapy and imaging

Also Published As

Publication number Publication date
LT3150227T (lt) 2018-12-10
PT2300054T (pt) 2016-11-11
SG10201405288WA (en) 2014-10-30
CY1118217T1 (el) 2017-06-28
WO2009147214A2 (en) 2009-12-10
LT2300054T (lt) 2016-12-27
DK3150227T3 (en) 2019-01-14
PL3150227T3 (pl) 2019-05-31
TR201819077T4 (tr) 2019-01-21
CY1121078T1 (el) 2019-12-11
MA32453B1 (fr) 2011-07-03
US8845507B2 (en) 2014-09-30
MX2010013322A (es) 2011-01-21
BRPI0913410B1 (pt) 2021-09-21
PT3150227T (pt) 2018-12-24
EA023012B1 (ru) 2016-04-29
AU2009254550A1 (en) 2009-12-10
HUE030669T2 (en) 2017-05-29
EP2300054A2 (en) 2011-03-30
HRP20161465T8 (hr) 2017-04-21
SI2300054T1 (sl) 2017-02-28
HRP20181993T1 (hr) 2019-01-25
EP2130553A1 (en) 2009-12-09
EP3150227B1 (en) 2018-10-31
EP3461502A1 (en) 2019-04-03
DK2300054T3 (en) 2016-12-05
IL209625A0 (en) 2011-02-28
ES2602048T3 (es) 2017-02-17
HRP20161465T1 (hr) 2017-01-27
AU2009254550B2 (en) 2013-10-24
CN102056628B (zh) 2013-07-10
KR101639281B1 (ko) 2016-07-13
EA201071429A1 (ru) 2011-06-30
EP3150227A1 (en) 2017-04-05
JP2011524866A (ja) 2011-09-08
CA2727576A1 (en) 2009-12-10
NZ589888A (en) 2012-06-29
CA2727576C (en) 2016-08-16
KR20110028616A (ko) 2011-03-21
SI3150227T1 (sl) 2019-02-28
ZA201100082B (en) 2011-10-26
US20110213192A1 (en) 2011-09-01
JP5734181B2 (ja) 2015-06-17
WO2009147214A3 (en) 2010-02-25
ES2702249T3 (es) 2019-02-28
CN102056628A (zh) 2011-05-11
HUE040247T2 (hu) 2019-02-28
IL209625A (en) 2015-11-30
PL2300054T3 (pl) 2017-04-28
EP2300054B1 (en) 2016-09-07

Similar Documents

Publication Publication Date Title
BRPI0917001A2 (pt) composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica
BRPI0917315A2 (pt) anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica
LTPA2018014I1 (lt) Farmacinė kompozicija 514
BRPI0908792A2 (pt) Composição, e, uso de uma combinação
BRPI0912717A2 (pt) Composição farmacêutica, e, uso de 5-azacitidina
BRPI0919942A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0813770A2 (pt) Composição, e, uso de uma composição
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BRPI1008039A2 (pt) composto, mistura, composição farmacêutica, e, uso de um coposto, de uma mistura ou de uma composição farmacêutica
BR112013001571A2 (pt) composto, composição farmacêutica, uso e método de prevenção ou tratamento de uma condição associada com a função do receptor gpr40
BRPI0917579A2 (pt) composto, composição farmacêutica, métodos, e, uso de um composto
BRPI0910557A2 (pt) composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e uso.
BRPI1005931A8 (pt) associação de compostos, uso de uma associação, produto em forma de kit, uso de um produto e composição farmacêutica
BRPI1013421A2 (pt) composição parasticida tópica, e, uso de uma composição
BRPI0816350A2 (pt) Composições orais, produtos e métodos de uso
BRPI0914793A2 (pt) Composição, e, uso de uma composição
BRPI1014316A2 (pt) composição, e, uso de uma composição
BRPI0918206A2 (pt) derivados de animoéster e composição medicinal destes
BRPI0906937A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI1006953A2 (pt) composição farmacêutica, e, uso de uma composição
BRPI0915473A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0920355A2 (pt) composições farmacêuticas tópicas estáveis de ozenoxacina e uso de ozenoxacina
BRPI0813587A2 (pt) Composto, uso do mesmo, e, composição farmacêutica

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/06/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.